Targeting the protein kinase ATP-binding pocket provides a significant opportunity for the treatment of disease. Recent studies have revealed a central activity-independent role for nucleotide pocket occupation in the allosteric behaviour of diverse kinases. Regulation of nucleotide pocket conformation with either nucleotides or ATP competitive inhibitors has revealed an added dimension to the targeting of kinases. In the present paper, using PKC (protein kinase C) as a paradigm, the liabilities and opportunities associated with the occupation of the nucleotide pocket are explored.
Introduction
Protein kinases are ubiquitous in eukaryotes, regulating almost every aspect of cellular behaviour from growth and development through to cell death. The success of this family of signalling proteins is reflected in their abundance, comprising approximately 2 % of all eukaryotic genes; more abundant than any other family of signalling enzymes [1, 2] . The key to this success lies in the flexibility of protein phosphorylation as a rapid and reversible modifier of protein function. While the evolution of kinases to exploit this mechanism has generated huge diversity, the core machinery that defines a kinase is remarkably well conserved throughout the kinome [3, 4] . This comprises a handful of key residues that co-ordinate ATP and aid catalysis. While focus has inevitably fallen on the catalytic transfer of phosphate from ATP to target proteins, the central importance of nucleotide binding in the regulation of kinase conformation has received less attention.
In the present mini-review, I will discuss the importance of nucleotide pocket occupation both in the context of the natural behaviour and function of kinases, and also in the context of intervention with nucleotide pocket-directed pharmacology.
domains [5] . Generally, this requires phosphorylation, or the presence of charged residues, at two key sites, termed the turn and hydrophobic motifs, within an AGC-family-specific C-terminal extension to the kinase domain. In addition, activity is controlled by phosphorylation of the more generic regulatory site within the kinase domain activation loop. Once phosphorylated the C-terminal tail is able to interact with a hydrophobic pocket on the surface of the N-lobe of the kinase domain. This hydrophobic pocket interaction, in conjunction with activation loop phosphorylation, serves to lock the kinase domain in a stable active conformation. While some AGC family members depend on autophosphorylation for occupation of these kinase domain priming sites, many fall under the jurisdiction of two master regulators: PDK1 (phosphoinositide-dependent kinase 1) for the activation loop and mTOR [mammalian TOR (target of rapamycin)] for the C-terminal motifs [6] [7] [8] .
Despite sharing common motifs and upstream kinases, distinct AGC family members are regulated in highly divergent ways dependent largely on additional regulatory elements [9] . Two informative examples of this divergence are PKB (protein kinase B) and PKC (protein kinase C). In the case of PKB, the kinase resides in an inactive conformation with the nucleotide pocket masked by an N-terminal PH domain (pleckstrin homology domain). On growth factor stimulation, phosphoinositide 3-kinasedependent recruitment of PKB to cell membranes allows the regulating kinases PDK1 and mTOR access to the activation loop (Thr 308 ) and hydrophobic motif (Ser 473 ) sites respectively, resulting in kinase domain phosphorylation and activation. In contrast, the PKC kinase domain is generally constitutively phosphorylated at all priming sites and adopts an activity-competent conformation. Access to the active site, however, is sterically hindered through binding of a pseudosubstrate sequence encoded within the N-terminal regulatory domain. Activation is achieved when recruitment Activation of PKC permits access to the active site and nucleotide exchange, which in turn sensitizes the kinase domain to phosphatase (PPase) attack. DAG, diacylglycerol; TORC2, TOR complex 2.
to cell membranes or binding of accessory proteins displaces the regulatory domain, allowing substrate access to the kinase-active site [10] .
Recent studies with a number of AGC family members have revealed an unexpected additional role for the nucleotide-binding pocket in regulating conformational stability and priming site occupancy. In the case of PKC, kinase-dead mutants, in which the key ATP-co-ordinating conserved lysine residue has been mutated, are poorly phosphorylated at all priming sites. Somewhat paradoxically however, these priming sites become phosphorylated when ATP-competitive inhibitors of PKC are introduced [11] . In contrast, kinase-dead mutants of PKC that retain wildtype binding contacts with ATP are phosphorylated at all three priming sites to wild-type levels. Analysis of analoguesensitive mutants of PKC reveals that this behaviour directly reflects the occupancy of the nucleotide-binding pocket. Thus occupation of the binding pocket with either ATP or an ATPcompetitive inhibitor favours priming site phosphorylation ( Figure 1 ), whereas ATP-binding-impaired mutants are more sensitive to dephosphorylation and thus accumulate in the unprimed state. This observation not only demonstrates a key role for nucleotide pocket integrity in stable priming, but also negates any requirement for autophosphorylation in the process.
In a physiological setting, nucleotide exchange and associated kinase domain phosphorylations are dynamic processes ( Figure 1 ). In the pseudosubstrate auto-inhibited state, access to the active site and associated nucleotide exchange is restricted, resulting in a stable fully phosphorylated latent state. Activation, either physiologically or with phorbol esters such as PMA, relieves auto-inhibition by the pseudosubstrate and permits nucleotide exchange. This is associated with increased dephosphorylation of the kinase domain priming sites. The rate of dephosphorylation is contingent on nucleotide pocket occupancy, as evidenced by the increased rate of dephosphorylation observed with mutants with a reduced ATP-binding capacity [12] . Such dephosphorylation is entirely blocked if the pocket is occupied with an inhibitor [11] . This model is also supported by in vitro experiments demonstrating that nucleotides and Mg 2+ protect PKC from dephosphorylation by PP2A (protein phosphatase 2A) [13] .
For PKB, introduction of ATP-competitive inhibitors can also directly promote phosphorylation of the activation loop and hydrophobic motif, independently of stimulus. Initially this observation was interpreted as evidence of a feedback control mechanism [14] . A more recent study, again employing the use of analogue-sensitive mutants, has demonstrated that, analogous to our work on PKC, PKB phosphorylation is promoted allosterically through occupation of the nucleotide-binding pocket [15] . These studies somewhat reverse the prevailing dogma that kinase domain phosphorylation drives the adoption of an active conformation by suggesting that small molecules, or indeed physiologically nucleotides, may drive the adoption of an active conformation, which can subsequently be locked by phosphorylation of the kinase domain priming sites. Such allosteric activation by small molecules is not limited to occupation of the nucleotide pocket. Small molecule allosteric activators that target the hydrophobic pocket of the AGC-type kinase PDK1 have been shown to drive the adoption of an active nucleotide pocket conformation by mimicking the structure stabilized when the hydrophobic pocket of PDK1 is occupied by the phosphorylated Cterminus [16, 17] . These mutually reversible relationships between pocket occupation, kinase domain conformation and phosphorylation are significant in the pharmacological targeting of this family of kinases.
Exploiting nucleotide pocket-driven PKC kinase domain maturation
The nucleotide pocket-dependent regulation of PKC maturation represents a significant opportunity for advancing our understanding of PKC biology and as a bonus provides a surprising tool for drug discovery. Although this system relies on mutant forms of PKC and non-physiological stimuli, it also exhibits distinct advantages. It provides us with a unique way to acutely control PKC phosphorylation and, consequently, provides a tool for probing the upstream pathways, i.e. the kinases and phosphatases acting on PKC. The direct allosteric mechanism through which inhibitors drive PKC phosphorylation circumvents potential complications associated with intermediate signalling events or activation of multiple signalling pathways. By making phosphomimetic mutations for the individual priming sites, we are able to dissociate the pathways that act at each site from each other. We have successfully exploited this approach to demonstrate that PDK1 is responsible specifically for activation loop phosphorylation in our system [11] . Our focus now falls on investigating the mechanism by which TORC2 (TOR complex 2) targets and regulates the phosphorylation of the two C-terminal sites.
As well as examining pathways that act upon PKC, we can also use the robust inhibitor-driven phosphorylation directly to screen compound libraries for inhibitors of PKC. Here, cells expressing kinase-dead PKC K437M are exposed to a library of kinase inhibitors and phosphorylation of the hydrophobic motif is used to monitor the efficacy of each compound to induce PKC priming. A pilot screen identified all known PKC inhibitors from a trial compound library, with the exception of inhibitors that also block one of the priming kinases [11] . This later complication can of course be exploited to screen libraries for inhibitors that block the priming process. Our 'in vivo' system for assaying inhibitor binding to PKC has the additional advantage of testing directly the ability of compounds to penetrate cells and access their targets under physiologically relevant conditions. Although I have focused here on compound libraries, these techniques can equally be applied to gene knockdown screens for directly identifying the proteins or pathways impinging on PKC phosphorylation.
Liabilities in targeting the ATP-binding pocket: unexpected activation of Raf by inhibitors
The dysregulation of kinase pathways in almost all diseases and the druggability of the kinase domain nucleotidebinding pocket have driven an explosion in the number of ATP competitive inhibitors in trials or in use in the clinic. Exploiting this pocket is not, however, without its complications as exemplified by the Raf kinases. Constitutive activation of the Raf-MEK [mitogen-activated protein kinase/ERK (extracellular-signal-regulated kinase) kinase]-ERK signalling cascade, predominantly through activating mutations in either B-Raf or the upstream Ras GTPases, is common to many cancers [18, 19] . Targeting Raf kinase activity in the clinic, however, has been seriously hampered by the observation that a number of distinct ATP-competitive inhibitors of Raf paradoxically drive the activation of both Raf and downstream signalling to ERK [20] [21] [22] . Analogous to our observations with PKC, ATP-competitive inhibitors were found to induce robust activating phosphorylation of Raf, hinting at a related mechanism of action.
While early studies once again attributed the activation of Raf to inhibition of a negative-feedback pathway, a number of papers have recently provided compelling evidence that the activation works through an allosteric mechanism [23] [24] [25] . Wild-type Raf is activated through the Rasdependent formation of B-Raf and C-Raf homo-and hetero- dimers. Using a combination of kinase-dead and analoguesensitive mutants, two groups independently demonstrated that binding of an inhibitor to one Raf subunit promotes transactivation of the dimer partner Raf subunit in a Rasdependent mechanism (Figure 2A ). This mechanism, in principle, is shown to hold true for both C-Raf and BRaf, but physiologically, transactivation of C-Raf appears to dominate. Significantly, while some inhibitors appear to robustly drive the dimerization of Raf, others appear to decrease dimer formation demonstrating the ability of distinct inhibitors to modulate target conformation and encouraging the development of allosteric inhibitors.
This mechanism does not work for Ras-independent activation of Raf. Thus with the common oncogenic V600E BRaf mutation, where neither Ras nor dimerization is required for activity, inhibitors are capable of inhibiting both B-Raf and downstream activation of the ERK cascade ( Figure 2B) . Indeed, treatment of melanoma patients bearing oncogenic mutations in B-Raf with the Raf inhibitor PLX4032 has shown promising results in the clinic [26, 27] , although the activation of Raf in other tissues or indeed in mutant Ras cells has been suggested as a potential liability to this therapy. These studies help inform us of both when and how we might target Raf effectively in cancer therapy and also highlight the potential complexities of drug-target interactions.
The gatekeeper residue: friend and foe
Our understanding of the structural importance of nucleotide pocket occupation in many kinases has been greatly aided by the development of analogue-sensitive kinases, pioneered by the Shokat laboratory [28, 29] . Here, the plasticity of the gatekeeper residue, which sits in the bottom of the ATP-binding pocket, can be exploited to generate mutants that are specifically inhibited by kinase inhibitor analogues. Mutations of this often bulky residue can open up an enlarged pocket within the base of the nucleotide-binding site, often without significantly affecting ATP-binding or kinase activity. Combing this with chemical modification of known kinase inhibitors can thus enable the generation of inhibitor 'analogues', which very specifically target the mutant kinase but not the wild-type or other unrelated kinases. Use of such mutants has been integral to the work described in this paper for PKC, PKB and Raf. In another striking example, Ire1, a kinase integral to the endoplasmic reticulum UPR (unfolded protein response), occupation of the nucleotide binding pocket with an inhibitor analogue has been shown to functionally bypass the need for kinase activity. Here, analogue-sensitive mutants also lack catalytic activity and fail to activate the UPR. Inhibition with the inhibitor analogue, however, rescues the ability of the mutant Ire1 to activate the UPR via a conformational change in the kinase domain in the absence of kinase activity [30] . Behaviours such as these would be difficult to authenticate without the development of this chemical genetics approach.
Nature unfortunately has been less kind in its exploitation of the gatekeeper residue. Inhibition of clinically validated oncogenic tyrosine kinases, including EGFR (epidermal growth factor receptor), PDGFR (platelet-derived growth factor receptor), c-Kit and BCR (breakpoint cluster region)-Abl, has become prevalent in the treatment of many human cancers, often with initially promising responses [31] . Unfortunately, resistance to TKI (tyrosine kinase inhibitor) therapy often arises and the gatekeeper residue is by far the most common escape route. Many tyrosine kinases have relatively small gatekeeper residues, often threonine, and mutations that substitute these residues for bulky side chains often render kinases resistant to inhibitors. Examples include the T790M mutation in EGFR resulting in TKIresistant lung cancer or the T315I mutation of BCR-Abl in chronic myelogenous leukaemia [32] . This has necessitated the development of new classes of inhibitors that target mutated versions of kinases [33, 34] or alternatively the development of inhibitors that lock inactive conformers of their target kinases such as the DFG-out inhibitors.
Perspectives: kinases are specialized nucleotide-binding effectors
Despite the versatility of protein phosphorylation as a modifier of protein function, structural and sequence-based bioinformatic analysis provides compelling evidence that all eukaryotic protein kinases, and the more distantly related eukaryotic-like kinases, probably arose from a single common ancestor [3, 4] . The evolutionarily conserved core comprises relatively few components: the F-helix bearing a critical aspartate residue, the catalytic loop HRD motif and the DFG motif-linked activation loop. Binding of ATP between these critical components completes the necessary equipment of catalysis and defines the constraints of the active kinase core. In this respect, ATP provides the foundation stone around which kinases have been built and have subsequently diversified to perform such a broad array of regulatory functions. It is perhaps of little surprise therefore to find that nucleotide occupancy plays such a critical structural role throughout the kinome. Indeed the presence of intact and occupied nucleotide-binding pockets within a number of recently described pseudokinase structures bears witness to the indispensability of nucleotide interaction, even when the requirement for phosphotransferase activity is lost [35, 36] . The constraints associated with an ATPoccupied active kinase domain coupled with the flexibility of inactive kinase structures provide fertile ground for allosteric regulation [37] . Exploiting the potential of this pocket to manipulate kinase conformation, and not just to block activity, is consequently of critical importance as we move forward in the targeting of kinases in disease.
